Refractive Outcomes And Patient Satisfaction After Implantation Of A New Trifocal Diffractive Intraocular Lens (Panoptix Clareon).

To describe the refractive, functional and patient´s satisfaction outcomes with the new Clareon material in PanOptix trifocal intraocular lens.

Miranza Begitek. Donostia - San Sebastián, Spain

Prospective study of 76 eyes of 38 patients undergoing lens surgery with implantation of PanOptix Clareon (Alcon laboratories, Inc.). Monocular and binocular visual acuity at distance, intermediate and near was evaluated at 1 and 6 months postoperatively. Refractive results, contrast sensitivity, defocus curve and patient satisfaction with IOLsat and QUVID questionaries were also assessed.

The mean age of our series of patients was 67.63±5.10 years. 

The 95% of the eyes obtained a monocular corrected-distanced visual acuity (CDVA) 0.16 logMAR or better at 1 month and 6 months. In monocular distance corrected intermediate (DCIVA) and near (DCVA) visual acuity, 95% of the eyes achieved 0.26 and 0.24 logMAR or better at 1 month and 6 months, respectively.

According to the IOLSat test, 62% of patients at distance, 70% at intermediate and 59% at near had good or very good vision without glasses in photopic conditions. 

According to the QUIVID test, 100% of the patients had no problems with color distortion and only 26% of the patients had some halos.

The new PanOptix IOL with Clareon material provides good visual outcomes at distance, intermediate and near vision during 6 months follow-up, with an adequate contrast sensitivity and low rate of visual disturbances.